GT
ABCL icon

Glenmede Trust’s AbCellera Biologics ABCL Stock Holding History

Glenmede Trust’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-69,459
Closed -$524K – 1257
2023
Q2 		$524K Hold
69,459
– – ﹤0.01% 814
2023
Q1 		$524K Buy
69,459
+774
+1% +$7.03K ﹤0.01% 817
2022
Q4 		$696K Buy
+68,685
New +$793K ﹤0.01% 746

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Glenmede Trust's ABCL Position: Q3 2023 in Review

Glenmede Trust sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 69,459 shares — an estimated $524K sold.

Glenmede Trust first reported a position in ABCL in Q4 2022 and held it in 3 quarters. The position peaked at $696K in Q4 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • Glenmede Trust reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • Glenmede Trust sold 69,459 AbCellera Biologics shares in Q3 2023, an estimated $524K.
  • Glenmede Trust first reported a position in AbCellera Biologics in Q4 2022 and held it in 3 quarters.
  • Glenmede Trust's AbCellera Biologics position peaked at $696K in Q4 2022.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Glenmede Trust's 13F filing for Q3 2023, filed 14 Nov 2023.